Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 78Triple Negative Breast Neoplasms 9Prostatic Neoplasms 8Colorectal Neoplasms 8Anatomic Stage I Breast Cancer AJCC v8 8Neoplasms 6Pancreatic Neoplasms 5Ovarian Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Neoplasm Metastasis 4Lung Neoplasms 4Breast Carcinoma In Situ 4Lymphedema 3Colonic Neoplasms 3Urinary Bladder Neoplasms 2Rectal Neoplasms 2Medication Adherence 2Fatigue 2Carcinoma, Intraductal, Noninfiltrating 2Breast Neoplasms, Male 2Anxiety Disorders 2Vomiting 1Uterine Cervical Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Signs and Symptoms 1Sarcoma 1Recurrence 1Radiodermatitis 1Pathologic Complete Response 1

Interventions

ixabepilone 1Standard of Care 1Practice Guidelines as Topic 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bilateral Breast Carcinoma × Standard of Care × Breast × Clear all
NCT00877500 2026-05-22

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
116 enrolled
Breast

Bilateral Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡